Status:

COMPLETED

Pilot Study of Closed-Loop Glucose Control in People With Type 1 Diabetes (BPK004)

Lead Sponsor:

University of Virginia

Collaborating Sponsors:

Juvenile Diabetes Research Foundation

Conditions:

Type 1 Diabetes

Eligibility:

All Genders

21+ years

Phase:

NA

Brief Summary

This study plans to link two existing technologies, the insulin pump and the continuous glucose monitor (CGM), to essentially develop an artificial pancreas, i.e., closed-loop. This will be done using...

Detailed Description

Each patient had an outpatient screening evaluation, and two 22 h overnight hospital admissions separated by a 2- to 4-week waiting period. Each inpatient admission began at 15:00 and ended at 13:00 o...

Eligibility Criteria

Inclusion

  • 21 years of age or older
  • Have Type 1 Diabetes Mellitus as defined by American Diabetes Association criteria or judgment of physician for at least 2 years (including those who may also be treated with metformin, thiazolidinedione, exenatide, or pramlintide).
  • Use of an insulin pump
  • If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, have stability on the medication for at least 1 month prior to enrollment in the study
  • Willingness to use lispro (Humalog) insulin for the duration of the inpatient study
  • Demonstration of proper mental status and cognition for the study

Exclusion

  • Age \<21
  • Pregnancy
  • Hematocrit \<36% (females); \<38% (males)
  • Symptomatic coronary artery disease (e.g. history of myocardial infarction, history of acute coronary syndrome, history of therapeutic coronary intervention, history of coronary bypass or stenting procedure, stable or unstable angina, episode of chest pain of cardiac etiology with documented EKG changes, positive stress test or catheterization with coronary blockages \>50%).
  • Congestive heart failure
  • History of a cerebrovascular event
  • Use of a medication that significantly impacts glucose metabolism (oral steroids)
  • Atrial fibrillation
  • Uncontrolled hypertension (resting blood pressure \>140/90)
  • History of a systemic or deep tissue infection with methicillin-resistant staph aureus or Candida albicans
  • Use of a device that may pose electromagnetic compatibility issues and/or radiofrequency interference with the FreeStyle NavigatorTM CGM (implantable cardioverter-defibrillator, electronic pacemaker, neurostimulator, intrathecal pump, and cochlear implants)
  • Active enrollment in another clinical trial
  • Allergy or adverse reaction to lispro insulin
  • Known adrenal gland problem, pancreatic tumor, or insulinoma
  • Current alcohol abuse, substance abuse, or severe mental illness
  • Retinopathy and renal failure
  • Uncontrolled anxiety or panic disorder
  • Known bleeding diathesis or dyscrasia
  • Renal insufficiency (creatinine \>1.5)
  • Any comorbid condition affecting glucose metabolism

Key Trial Info

Start Date :

May 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2009

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT00977808

Start Date

May 1 2008

End Date

February 1 2009

Last Update

September 4 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Virginia

Charlottesville, Virginia, United States, 22904